社区非健壮与健壮老年人水痘-带状疱疹疫苗免疫原性比较:前瞻性队列研究
研究纳入69名≥65岁社区老年人,接种带状疱疹减毒活疫苗(ZVL)前评估衰弱状态与细胞因子水平,接种6周后检测体液与细胞免疫原性。结果显示健壮与非健壮组抗体几何平均倍数上升相似,基线细胞因子水平与免疫原性无显著相关,提示ZVL可在非健壮(尤其衰弱前期)及健壮老年人中增强免疫。
要点
- 接种后6周,至少10个斑点形成细胞/10^6 PBMC的参与者从35名增至57名(增加22名)。
- 健壮与非健壮组抗体几何平均倍数上升相似,基线细胞因子与免疫原性无显著相关。
核心结论
- ZVL可在非健壮(尤其衰弱前期)及健壮社区老年人中增强免疫,衰弱状态未显著影响抗体几何平均倍数上升。
研究设计与样本
- 前瞻性队列研究,纳入69名≥65岁社区老年人(平均年龄74.3岁),其中31名为非健壮,接种ZVL前评估衰弱状态与细胞因子水平,接种前及接种6周后检测体液与细胞免疫原性。
主要发现
- 接种6周后,至少10个斑点形成细胞/10^6 PBMC的参与者从35名增至57名(增加22名)。
- 接种6周后,42名参与者斑点形成细胞几何平均倍数上升2倍。
- 健壮与非健壮组抗体几何平均倍数上升相似,基线及接种6周后酶联免疫斑点法几何均值无显著差异。
- 基线细胞因子水平与免疫原性无显著相关性。
临床怎么用
- 对社区非健壮(尤其衰弱前期)及健壮老年人,可考虑接种ZVL以增强带状疱疹免疫。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To determine whether immunogenicity of the herpes zoster live-attenuated vaccine (ZVL) in elderly individuals is influenced by frailty status and cytokine levels, individuals aged at least 65 years were prospectively administered ZVL after their frailty status and cytokine levels were assessed. Humoral and cellular immunogenicity were assessed using enzyme-linked immunosorbent assays for the varicella-zoster virus-specific IgG antibody and varicella-zoster virus-specific enzyme-linked immunospot assays, before and 6 weeks after vaccination. We enrolled 69 participants (mean age, 74.3 years); 31 were non-robust. Thirty-seven participants had a greater than 2 geometric mean fold rise in IgG antibodies, 22 more participants had at least 10 spot-forming cells/106 peripheral blood mononuclear cells (from 35 to 57 participants), and 42 experienced a twofold geometric mean fold rise increase of spot-forming cells 6 weeks after vaccination. The geometric mean fold rises of the antibody titers were similar in the robust and non-robust groups; moreover, the baseline enzyme-linked immunospot assay geometric mean values were not significantly different before or 6 weeks after vaccination. We observed no significant correlations between baseline cytokine levels and immunogenicity. Approximately half of the community-dwelling elderly participants in this study experienced a twofold rise in antibodies and one-third more participants showed at least 10 spot-forming cells after ZVL administration, suggesting that the ZVL can boost immunity in non-robust (especially pre-frail) and robust elderly individuals.
引用
- Choi JY, Kang MG, Park KU, et al. Immunogenicity of the Varicella-Zoster Vaccine in Community-Dwelling Non-robust Elderly Individuals Compared to Robust Elderly Individuals: A Prospective Cohort Study. J Gerontol A Biol Sci Med Sci. 2019. PMID: 30576411. doi:10.1093/gerona/gly287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。